Get access

Inhibitors in childhood hemophilia A: Genetic and treatment-related risk factors for development and eradication

Authors

  • Donna M. DiMichele MD

    Corresponding author
    1. Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
    • Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute, 6701 Rockledge Drive, Room 9132, Bethesda, MD 20892-7950.
    Search for more papers by this author

  • Conflict of Interest: Nothing to declare.

  • Wiley has published this supplement with financial support from the Hospital for Sick Children in Toronto [non-commercial entity].

Abstract

The development of neutralizing antibodies remains a serious complication of hemophilia replacement therapy. Factor VIII inhibiting antibodies (inhibitors) occur commonly following replacement therapy in hemophilia A, creating a significant burden of clinical disease. This article will review our current understanding of risk factors and their known impact on inhibitor development in previously untreated or minimally treated children with severe and mild hemophilia A. It will also explore how the most recently elucidated immunology of inhibitor development might hold important clues to more effective inhibitor eradication and prevention in this heavily impacted patient population. Pediatr Blood Cancer 2012; 60: S30–S33. © 2012 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary